Celgene Inc., in collaboration with Health Canada, would like to inform you of important new safety information which has been added to the Product Monograph for REVLIMID® (lenalidomide) capsules. REVLIMID® is indicated in combination with dexamethasone for the treatment of multiple myeloma (MM) in patients who have received at least one prior therapy. Read more
here.
No comments:
Post a Comment